Results

1–10 of 55 results for Anti-VEGF Agents

LEAVO vs. SCORE2: A Comparison of Two CRVO Comparative-Effectiveness Trials for the Treatment of Macular Edema With Anti-VEGF Agents
Barbara A. Blodi, MD
Updates from the Field
2019
Episode 29: Anti-VEGF Levels in Breast Milk after Intravitreal Injections- Drs. Muni and Juncal
Keyvan Koushan, MD, FRCSC
Member Podcasts
Dual Targeting VEGF/Ang3 Surrobody in an Experimental Model of Neovascularization
Jeffrey L. Olson, MD
Annual Meeting Talks
Episode 28: Brolucizumab for wet AMD (HAWK and HARRIER) - Dr. Pravin Dugel
Keyvan Koushan, MD, FRCSC
Member Podcasts
Retinal Vascular Disease Take-Home Panel
Neil M. Bressler, MD
Annual Meeting Talks
Vision Threatening Complications in Patients With Diabetic Macular Edema: A Post Hoc Analysis of the VISTA and VIVID Trials
Diana V Do, MD
Annual Meeting Talks
The Average Patient Does Not Enter Your Office: What Can We Learn About Treating nAMD From Individual Patient Responses
David S. Boyer, MD
Annual Meeting Talks
Port Delivery System With Ranibizumab: Key Outcomes From the Ladder Phase 2 Trial That Supported Archway Phase 3 Study Design
Arshad M. Khanani, MD
Annual Meeting Talks
First Results From a Phase 1B Multiple-Dose Study of KSI-301: A Novel Anti-VEGF Antibody Biopolymer Conjugate (ABC) With Extended Durability
Pravin U. Dugel, MD
Annual Meeting Talks
Geographic Atrophy in the Canadian Treat and Extend Trial With Ranibizumab in nAMD Patients: CANTREAT Study 24-Month Results
Peter J. Kertes, MD, FRCS(C)
Annual Meeting Talks